Pfizer's maternal RSV vaccine filing gets priority review, setting up showdown with AstraZeneca, Sanofi

Pfizer is ready to ram home its advantage in the respiratory syncytial virus (RSV) maternal vaccine race. With onetime close rival GSK still stalled, the Big Pharma has put itself on course to receive a landmark approval by August and go on to challenge AstraZeneca and Sanofi’s long-acting antibody for the market.